It is possible that attenuated β-blocker efficacy is RyR2 mutation-specific, as KCNQ1 mutation-specific responses to β-blocker therapy have been observed in type I long QT syndrome, another inherited arrhythmogenic channelopathy (Barsheshet et al., 2012). Here, KCNQ1 is linked to channelopathy.